Lexeo Therapeutics, Inc. Common StockLXEONASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank57
3Y CAGR-36.0%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-36.0%/yr
Quarterly compound
Percentile
P57
Within normal range
vs 3Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 6.62% |
| Q2 2025 | -14.27% |
| Q1 2025 | -6.51% |
| Q4 2024 | -21.59% |
| Q3 2024 | 41.44% |
| Q2 2024 | 5.20% |
| Q1 2024 | 91.74% |
| Q4 2023 | -52.39% |
| Q3 2023 | 53.49% |
| Q2 2023 | -31.65% |
| Q1 2023 | 44.36% |
| Q4 2022 | -25.88% |
| Q3 2022 | 25.23% |
| Q2 2022 | 20.90% |
| Q1 2022 | 0.00% |